VIP Expands Its Immune Role: Controlling Th17 Cells in Addition to Th1 and Tregs

VIP regulation of immune responses expanded beyond Th1/Treg balance to include Th17 cell modulation, with VIP suppressing pathogenic Th17 differentiation — broadening its anti-autoimmune therapeutic potential.

Yadav, Mahesh et al.·Annals of the New York Academy of Sciences·2008·Moderate EvidenceReview
RPEP-01438ReviewModerate Evidence2008RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

VIP's immunomodulatory spectrum expanded to include Th17 cell regulation: suppressing pathogenic IL-17 producing cells in addition to its established Th1 suppression and Treg promotion — comprehensive anti-autoimmune peptide with Th1/Th17/Treg triple regulation.

Key Numbers

How They Did This

review study.

Why This Research Matters

Relevant for neuropeptides, immune-function, inflammation.

The Bigger Picture

Advances peptide research.

What This Study Doesn't Tell Us

See abstract.

Questions This Raises

  • ?Further research needed.
  • ?Clinical translation to evaluate.

Trust & Context

Key Stat:
Key finding VIP's immunomodulatory spectrum expanded to include Th17 cell regulation: suppressing pathogenic IL-17 producing cells in addition to its established
Evidence Grade:
moderate evidence.
Study Age:
Published in 2008.
Original Title:
Vasoactive intestinal peptide-mediated Th17 differentiation: an expanding spectrum of vasoactive intestinal peptide effects in immunity and autoimmunity.
Published In:
Annals of the New York Academy of Sciences, 1144, 83-9 (2008)
Database ID:
RPEP-01438

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

What was studied?

VIP Expands Its Immune Role: Controlling Th17 Cells in Addition to Th1 and Tregs

What was found?

VIP regulation of immune responses expanded beyond Th1/Treg balance to include Th17 cell modulation, with VIP suppressing pathogenic Th17 differentiation — broadening its anti-autoimmune therapeutic potential.

Read More on RethinkPeptides

Cite This Study

RPEP-01438·https://rethinkpeptides.com/research/RPEP-01438

APA

Yadav, Mahesh; Goetzl, Edward J. (2008). Vasoactive intestinal peptide-mediated Th17 differentiation: an expanding spectrum of vasoactive intestinal peptide effects in immunity and autoimmunity.. Annals of the New York Academy of Sciences, 1144, 83-9. https://doi.org/10.1196/annals.1418.020

MLA

Yadav, Mahesh, et al. "Vasoactive intestinal peptide-mediated Th17 differentiation: an expanding spectrum of vasoactive intestinal peptide effects in immunity and autoimmunity.." Annals of the New York Academy of Sciences, 2008. https://doi.org/10.1196/annals.1418.020

RethinkPeptides

RethinkPeptides Research Database. "Vasoactive intestinal peptide-mediated Th17 differentiation:..." RPEP-01438. Retrieved from https://rethinkpeptides.com/research/yadav-2008-vasoactive-intestinal-peptidemediated-th17

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.